JP7385566B2 - 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 - Google Patents

突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 Download PDF

Info

Publication number
JP7385566B2
JP7385566B2 JP2020530325A JP2020530325A JP7385566B2 JP 7385566 B2 JP7385566 B2 JP 7385566B2 JP 2020530325 A JP2020530325 A JP 2020530325A JP 2020530325 A JP2020530325 A JP 2020530325A JP 7385566 B2 JP7385566 B2 JP 7385566B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tcr
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020530325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505136A (ja
JP2021505136A5 (enExample
Inventor
ヨセフ、ラミ
ルー、ヨン－チェン
カフリ、ガル
エー． ローゼンバーグ、スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2021505136A publication Critical patent/JP2021505136A/ja
Publication of JP2021505136A5 publication Critical patent/JP2021505136A5/ja
Priority to JP2023133670A priority Critical patent/JP7620676B2/ja
Application granted granted Critical
Publication of JP7385566B2 publication Critical patent/JP7385566B2/ja
Priority to JP2025003895A priority patent/JP2025072378A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
JP2020530325A 2017-12-04 2018-12-03 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体 Active JP7385566B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023133670A JP7620676B2 (ja) 2017-12-04 2023-08-18 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP2025003895A JP2025072378A (ja) 2017-12-04 2025-01-10 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762594244P 2017-12-04 2017-12-04
US62/594,244 2017-12-04
PCT/US2018/063581 WO2019112941A1 (en) 2017-12-04 2018-12-03 Hla class i-restricted t cell receptors against mutated ras

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133670A Division JP7620676B2 (ja) 2017-12-04 2023-08-18 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体

Publications (3)

Publication Number Publication Date
JP2021505136A JP2021505136A (ja) 2021-02-18
JP2021505136A5 JP2021505136A5 (enExample) 2022-01-11
JP7385566B2 true JP7385566B2 (ja) 2023-11-22

Family

ID=64949411

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020530325A Active JP7385566B2 (ja) 2017-12-04 2018-12-03 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP2023133670A Active JP7620676B2 (ja) 2017-12-04 2023-08-18 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP2025003895A Pending JP2025072378A (ja) 2017-12-04 2025-01-10 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023133670A Active JP7620676B2 (ja) 2017-12-04 2023-08-18 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
JP2025003895A Pending JP2025072378A (ja) 2017-12-04 2025-01-10 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体

Country Status (15)

Country Link
US (2) US11466071B2 (enExample)
EP (1) EP3720478A1 (enExample)
JP (3) JP7385566B2 (enExample)
KR (1) KR20200115484A (enExample)
CN (2) CN111836638B (enExample)
AU (2) AU2018378200B2 (enExample)
BR (1) BR112020011111A2 (enExample)
CA (1) CA3084246A1 (enExample)
CR (1) CR20200287A (enExample)
EA (1) EA202091335A1 (enExample)
IL (1) IL275031A (enExample)
MA (2) MA51043A (enExample)
MX (1) MX2020005765A (enExample)
SG (1) SG11202005236QA (enExample)
WO (1) WO2019112941A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3635000A4 (en) * 2017-05-16 2021-04-14 The Johns Hopkins University Manabodies and methods of using
US20220088190A1 (en) * 2019-01-25 2022-03-24 The Trustees Of The University Of Pennsylvania Compositions and Methods for Targeting Mutant RAS
GB2596461B (en) 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
EP3760217A1 (en) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
GB2609760A (en) * 2020-02-12 2023-02-15 Us Health HLA Class I-restricted T cell receptors against RAS with G12D mutation
WO2021163477A1 (en) * 2020-02-14 2021-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against ras with g12v mutation
CN115244075A (zh) * 2020-02-26 2022-10-25 美国卫生和人力服务部 针对含有g12v突变的ras的hla ii类限制性t细胞受体
EP4182029A1 (en) * 2020-07-16 2023-05-24 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted drb t cell receptors against ras with g12v mutation
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
KR102488353B1 (ko) * 2020-10-08 2023-01-12 부산대학교 산학협력단 돌연변이 kras를 표적하는 펩타이드 및 이의 용도
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体
US20240175047A1 (en) 2021-02-25 2024-05-30 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
WO2022251283A1 (en) * 2021-05-25 2022-12-01 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
US20250101078A1 (en) 2022-01-21 2025-03-27 T-Knife Gmbh Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN115960204B (zh) * 2022-11-04 2023-08-25 新景智源生物科技(苏州)有限公司 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
WO2025056672A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C
WO2025125590A2 (en) * 2023-12-15 2025-06-19 Genovie Ab Tcr recognizing g12v mutated ras and uses thereof
EP4570263A1 (en) * 2023-12-15 2025-06-18 Genovie AB Tcrs recognizing g12v mutated ras and uses thereof
CN119350472B (zh) * 2024-12-25 2025-04-04 北京可瑞生物科技有限公司 修饰的靶向kras g12v的t细胞受体或其片段以及用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085904A1 (en) 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CN103124740B (zh) * 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP3901169A1 (en) * 2015-09-15 2021-10-27 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
EP3394092A1 (en) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
JP6697562B2 (ja) * 2015-12-23 2020-05-20 メディジーン イミュノテラピーズ ゲーエムベーハー 樹状細胞組成物
US12221627B2 (en) * 2017-12-04 2025-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085904A1 (en) 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Immunology Research，2016年03月，Vol.4, No.3 ，pp.204-214，https://aacrjournals.org/cancerimmunolres/article/4/3/204/468486/Identification-of-T-cell-Receptors-Targeting-KRAS参照

Also Published As

Publication number Publication date
WO2019112941A1 (en) 2019-06-13
CN119162251A (zh) 2024-12-20
CA3084246A1 (en) 2019-06-13
JP2021505136A (ja) 2021-02-18
SG11202005236QA (en) 2020-07-29
CN111836638A (zh) 2020-10-27
JP2023175703A (ja) 2023-12-12
KR20200115484A (ko) 2020-10-07
IL275031A (en) 2020-07-30
AU2018378200A1 (en) 2020-07-02
US20210079058A1 (en) 2021-03-18
BR112020011111A2 (pt) 2020-11-17
EP3720478A1 (en) 2020-10-14
US11466071B2 (en) 2022-10-11
US20230026180A1 (en) 2023-01-26
EA202091335A1 (ru) 2020-10-15
CN111836638B (zh) 2024-10-29
MA51042A (fr) 2020-10-14
MA51043A (fr) 2020-10-14
JP7620676B2 (ja) 2025-01-23
AU2018378200B2 (en) 2025-02-27
JP2025072378A (ja) 2025-05-09
MX2020005765A (es) 2020-09-25
AU2025203455A1 (en) 2025-06-05
CR20200287A (es) 2020-11-11

Similar Documents

Publication Publication Date Title
JP7620676B2 (ja) 突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
EP3223850B1 (en) Anti-mutated kras t cell receptors
JP7735285B2 (ja) Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
US20230080742A1 (en) Hla class i-restricted t cell receptors against ras with g12d mutation
US20200129555A1 (en) Hla-a3-restricted t cell receptors against mutated ras
JP7742354B2 (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
JP2024517884A (ja) ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体
JP2025114614A (ja) Ｇ１２ｒ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
US20210115108A1 (en) T cell receptors which recognize mutated egfr
US20230257440A1 (en) Hla class ii-restricted drb t cell receptors against ras with g12v mutation
RU2849866C1 (ru) T-клеточные рецепторы, рестриктированные по hla класса i, против ras с мутацией g12d
US20240190940A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
HK40031837B (en) Anti-mutated kras t cell receptors
EA045513B1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
HK1243642B (en) Anti-mutated kras t cell receptors

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231110

R150 Certificate of patent or registration of utility model

Ref document number: 7385566

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150